Liquid Biopsy
News and reporting on cell-free DNA testing.
A discussion at last week's Precision Medicine Tri-Con demonstrated that stakeholders are narrowing in on the challenges to realizing the promise of solid tumor MRD.
The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.
Guardant Health's Shield Colorectal Cancer Blood Test Garners CMS Advanced Diagnostic Status
The test will be reimbursed at the price of $1,495 for Medicare patients during the initial nine-month ADLT period starting on April 1.
CityUHK, Cellomics to Develop Circulating Tumor Cell Screening Platform
Within two years, the team hopes to commercialize an assay that combines cell sorting, staining, and imaging, as well as protein and gene profiling.
Tethis, Sheba Medical Center Trying to Predict Rectal Cancer Relapse Earlier With CTCs, ctDNA
Sheba researchers will use Tethis' technology to prepare patients' blood samples for circulating tumor cells and circulating tumor DNA analysis.